Clinical Trial

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2017-07-26; most recent amendment 2025-09-30.
Status change: Recruiting → Active, Not Recruiting 2022-07-05
Status change: Not Yet Recruiting → Recruiting 2018-04-30
Trial Details
NCT Number NCT03233347
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Enrollment 82 participants
Start Date 2017-10-13
Primary Completion 2025-07-01 (estimated)
Study Completion 2026-07-08 (estimated)
Updated on ClinicalTrials.gov 2025-10-03